Cyclin D3 gene amplification in bladder carcinoma in situ

Virchows Archiv

Volumn 457, Issue 5, 2010, Pages 555-561

  Lopez Beltran, Antonio ^a   Ordóñez, Jose L ^b   Otero, Ana P ^b   Blanca, Ana ^c   Sevillano, Vicky ^b   Sanchez Carbayo, Marta ^d   Muñoz, Elisa ^c   Cheng, Liang ^e   Montironi, Rodolfo ^f   De Alava, Enrique ^b  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e INDIANA UNIVERSITY   (United States)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Bladder; Carcinoma in situ; Cyclin D3; Gene amplification

Indexed keywords

BCG VACCINE; CYCLIN D3;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL ARTICLE; CYSTECTOMY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGRESSION ANALYSIS; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; BCG VACCINE; BLOTTING, WESTERN; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CYCLIN D3; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 78149469992     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-010-0969-6     Document Type: Article

References (28)

1. A Lopez-Beltran 2008 Bladder cancer: clinical and pathological profile Scand J Urol Nephrol Suppl 218 95 109 10.1080/03008880802325226
2. N Nese R Gupta MH Bui MB Amin 2009 Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis J Natl Compr Canc Netw 7 48 57 19176205
3. P Andius O Damm S Holmäng 2004 Prognostic factors in patients with carcinoma in situ treated with intravesical Bacille Calmette-Guérin Scand J Urol Nephrol 38 285 290 10.1080/00365590410028692 15669587 (Pubitemid 39277287)
4. JA Witjes 2004 Bladder carcinoma in situ in 2003: state of the art Eur Urol 45 142 146 1:STN:280:DC%2BD2c%2FjsVClsg%3D%3D 10.1016/j.eururo.2003.09.013 14733997 (Pubitemid 38147818)
5. AP van der Meijden R Sylvester W Oosterlinck 2005 EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ Eur Urol 48 363 371 15994003
6. RJ Sylvester A van der Meijden JA Witjes 2005 High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder Urology 66 Suppl 1 90 107 10.1016/j.urology.2005.06.135 16399418 (Pubitemid 43049611)
7. SF Shariat GS Palapattu PI Karakiewicz 2007 Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy Eur Urol 51 152 160 10.1016/j.eururo.2006.08.037 17011114 (Pubitemid 44821530)
8. R Montironi A Lopez-Beltran M Scarpelli R Mazzucchelli L Cheng 2009 2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections Eur Urol Suppl 8 453 457
9. L Cheng JC Cheville RM Neumann 1999 Survival of Patients with Carcinoma In Situ of the Urinary Bladder Cancer 85 2469 2474 1:STN:280: DyaK1M3osVeisA%3D%3D 10.1002/(SICI)1097-0142(19990601)85:11<2469::AID- CNCR24>3.0.CO;2-U 10357420 (Pubitemid 29244858)
10. R Gonzalez-Campora G Davalos-Casanova A Beato-Moreno A Lopez-Beltran 2007 BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma Cancer Lett 250 292 299 1:CAS:528:DC%2BD2sXjvFGqtbc%3D 10.1016/j.canlet.2006.10.011 17126995 (Pubitemid 46529448)
11. ON Gofrit D Pode G Pizov 2009 The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Gúerin immunotherapy Urol Oncol 27 258 262 18440839
12. H Wolf F Melsen SE Pedersen KT Nielsen 1994 Natural history of carcinoma in situ of the urinary bladder Scand J Urol Néphrol Suppl 157 147 151
13. J Palou P Laguna F Millan-Rodriguez RR Hall J Salvador-Bayarri J Vicente-Rodriguez 2001 Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors J Urol 165 1488 1491 1:STN:280:DC%2BD3M3ovVOjsA%3D%3D 10.1016/S0022-5347(05)66333-1 11342902
14. MJ Ribal A Alcaraz L Mengual 2004 Chromosomal High-Polysomies Predict Tumour Progression in T1 Transitional Cell Carcinoma of the Bladder Eur Urol 45 593 599 1:STN:280:DC%2BD2c7osFOnsQ%3D%3D 10.1016/j.eururo.2003.12.013 15082201 (Pubitemid 38481686)
15. SF Shariat J Kim G Raptidis GE Ayala SP Lerner 2003 Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder Urology 61 1140 1145 10.1016/S0090-4295(03)00236-X 12809883 (Pubitemid 36693989)
16. AH Hopman MA Kamps EJ Speel RF Schapers G Sauter FC Ramaekers 2002 Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma Am J Pathol 161 1119 1125 1:CAS:528:DC%2BD38XotlyqtbY%3D 12368185
17. SF Shariat S Pahlavan AG Baseman 2001 E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder Urology 57 60 65 1:STN:280:DC%2BD3M3is1equg%3D%3D 10.1016/S0090-4295(00)00892-X 11164145 (Pubitemid 32065821)
18. AR Zlotta JC Noel I Fayt 1999 Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy J Urol 161 792 798 1:STN:280:DyaK1M7ksFartg%3D%3D 10.1016/S0022-5347(01)61770-1 10022686 (Pubitemid 29422368)
19. A Hartmann G Schlake D Zaak 2002 Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder Cancer Res 62 809 818 1:CAS:528:DC%2BD38Xht1Kru70%3D 11830537
20. L Dyrskjøt M Kruhøffer T Thykjaer 2004 Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification Cancer Res 64 4040 4048 10.1158/0008-5472.CAN-03-3620 15173019 (Pubitemid 38697320)
21. K Zieger N Marcussen M Borre TF Orntoft L Dyrskjøt 2009 Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development Int J Cancer 125 2095 2103 1:CAS:528:DC%2BD1MXhtVOms7bE 10.1002/ijc.24619 19637316
22. A Lopez-Beltran L Cheng R Mazzucchelli A Blanca R Montironi 2008 Morphological and Molecular Profiles and Pathways in Bladder Neoplasms Anticancer Res 28 2893 2900 19031931
23. BP Schrier JL Vriesema JA Witjes LA Kiemeney JA Schalken 2006 The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma Eur Urol 50 76 82 1:CAS:528:DC%2BD28XnsFWmsbs%3D 10.1016/j.eururo.2005.12.041 16413663 (Pubitemid 43850109)
24. A Lopez-Beltran MJ Requena RJ Luque J Alvarez R Montironi 2006 Cyclin D3 expression in primary Ta/T1 bladder cancer J Pathol 209 106 113 1:CAS:528:DC%2BD28XkvVSmtLc%3D 10.1002/path.1952 16482499
25. A Lopez-Beltran RJ Luque J Alvarez-Kindelan R Montironi 2004 Prognostic Factors in StageT1Grade 3 Bladder Cancer Survival: The Role of G1+S Modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and Proliferation Index (ki67-MIB1) Eur Urol 45 606 612 1:CAS:528:DC%2BD2cXksVWju7o%3D 10.1016/j.eururo.2003.11.011 15082203 (Pubitemid 38481688)
26. J Bartkova M Zemanova J Bartek 1996 Abundance and subcellular localization of cyclin D3 in human tumors Int J Cancer 65 323 327 1:CAS:528:DyaK28Xhs1Shs7s%3D 10.1002/(SICI)1097-0215(19960126)65:3<323::AID- IJC8>3.0.CO;2-1 8575852 (Pubitemid 26059986)
27. M Birkhahn AP Mitra AJ Williams 2010 Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles Eur Urol 57 12 20 1:CAS:528:DC%2BC3cXls1ahu7g%3D 10.1016/j.eururo.2009.09.013 19762144
28. G Pruneri L Pignataro S Valentini 2005 Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma Clin Cancer Res 11 242 248 1:CAS:528:DC%2BD2MXhtVegsb0%3D 15671552